Phase 1/2 study with our HDAC inhibitor mocetinostat in combination with MedImmune’s PD-L1 inhibitor MEDI4736 in patients with Advanced Solid Tumors and NSCLC - Regional Cancer Care Associates LLC

Clinical Trials

Phase 1/2 study with our HDAC inhibitor mocetinostat in combination with MedImmune’s PD-L1 inhibitor MEDI4736 in patients with Advanced Solid Tumors and NSCLC

Type of Cancer

Warning: implode(): Invalid arguments passed in /home/region33/public_html/wp-content/themes/regionalcancercenter/single-clinical-trials.php on line 42
Locations
Sponsor
Mirati Therapeutics
Protocol Number
Mirati 0103-020
Cancer Diagnosis
To Learn More Call
201-510-0910